Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC)

被引：8
|
作者：
Patel, J. D.
Hensing, T. A.
Rademaker, F.
Hart, E.
Obasaju, C. K.
Treat, J.
Milton, D.
Bonomi, P. D.
机构：
[1] Northwestern Univ, Chicago, IL 60611 USA
[2] Evanston Northwestern Healthcare, Evanston, IL USA
[3] Lilly Oncol, Indianapolis, IN USA
[4] St Vincents Hosp, Indianapolis, IN USA
[5] Rush Univ, Med Ctr, Chicago, IL 60612 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.8044
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8044
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer
    Spigel, David R.
    Hainsworth, John D.
    Shipley, Dianna L.
    Ervin, Thomas J.
    Kohler, Peter C.
    Lubiner, Eric T.
    Peyton, James D.
    Waterhouse, David M.
    Burris, Howard A., III
    Greco, F. Anthony
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (01) : 196 - 202
  • [22] Multicenter phase II study of cisplatin, pemetrexed, plus bevacizumab followed by maintenance pemetrexed plus bevacizumab for patients with advanced or recurrent non-squamous non-small cell lung cancer: MAP study
    Tsutani, Y.
    Miyata, Y.
    Masuda, T.
    Fujitaka, K.
    Doi, M.
    Awaya, Y.
    Kuyama, S.
    Kitaguchi, S.
    Ueda, K.
    Okada, M.
    ANNALS OF ONCOLOGY, 2017, 28 : 137 - 137
  • [23] Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer
    Fukushima, Toshirou
    Wakatsuki, Yuuki
    Kobayashi, Takashi
    Sonehara, Kei
    Tateishi, Kazunari
    Yamamoto, Manabu
    Masubuchi, Takeshi
    Yoshiike, Fumiaki
    Hirai, Kazuya
    Hachiya, Tsutomu
    Koizumi, Tomonobu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (06) : 1043 - 1050
  • [24] Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer
    Toshirou Fukushima
    Yuuki Wakatsuki
    Takashi Kobayashi
    Kei Sonehara
    Kazunari Tateishi
    Manabu Yamamoto
    Takeshi Masubuchi
    Fumiaki Yoshiike
    Kazuya Hirai
    Tsutomu Hachiya
    Tomonobu Koizumi
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 1043 - 1050
  • [25] A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer.
    Spigel, D. R.
    Greco, F. A.
    Shipley, D.
    Ervin, T. J.
    Lubiner, E. T.
    Peyton, J. D.
    Bames, E. K.
    Thompson, D. S.
    Burris, H. A., III
    Hainsworth, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [26] First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naive patients
    Leon, Luis
    Vazquez, Sergio
    Manuel Gracia, Jose
    Casal, Joaquin
    Lazaro, Martin
    Luis Firvida, Jose
    Amenedo, Margarita
    Santome, Lucia
    Macia, Sonia
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (10) : 1389 - 1396
  • [27] The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC)
    Ding, Lingyu
    Liu, Kejun
    Jiang, Zhelong
    Chen, Qi
    Zhou, Ningning
    Liang, Ying
    Gao, Hongfei
    Hong, Xiangchan
    Wu, Haiying
    TUMOR BIOLOGY, 2015, 36 (04) : 2491 - 2499
  • [28] Randomized phase II trial of pemetrexed with or without bevacizumab maintenance after cisplatin, pemetrexed and bevacizumab in advanced non-squamous, non-small cell lung cancer (TORG1321)
    Kondo, T.
    Kasai, T.
    Mori, K.
    Saito, H.
    Nishikawa, K.
    Otsu, S.
    Seki, N.
    Ichikawa, Y.
    Bessho, A.
    Tanaka, H.
    Yamaguchi, H.
    Kaburagi, T.
    Kanazawa, K.
    Komase, Y.
    Minato, K.
    Misumi, Y.
    Morinaga, R.
    Mori, K.
    Ohtake, J.
    Okamoto, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S875 - S875
  • [29] Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study
    Koji Nishimoto
    Masato Karayama
    Naoki Inui
    Hideki Yasui
    Hironao Hozumi
    Yuzo Suzuki
    Kazuki Furuhashi
    Tomoyuki Fujisawa
    Noriyuki Enomoto
    Yutaro Nakamura
    Nao Inami
    Shun Matsuura
    Yusuke Kaida
    Takashi Matsui
    Kazuhiro Asada
    Hiroyuki Matsuda
    Masato Fujii
    Mikio Toyoshima
    Shiro Imokawa
    Takafumi Suda
    Medical Oncology, 2018, 35
  • [30] Treatment with or without bevacizumab as a first-line and maintenance therapy for advanced non-squamous non-small cell lung cancer: A retrospective study
    Ni Jun
    Wang Hanping
    Si Xiaoyan
    Xu Yan
    Wang Mengzhao
    Zhang Xiaotong
    Zhang Li
    THORACIC CANCER, 2020, 11 (07) : 1869 - 1875
12345